Literature DB >> 12778490

The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells.

Tuure Kinnunen1, Cecile Buhot, Ale Närvänen, Marja Rytkönen-Nissinen, Soili Saarelainen, Sandra Pouvelle-Moratille, Jaakko Rautiainen, Antti Taivainen, Bernard Maillère, Rauno Mäntyjärvi, Tuomas Virtanen.   

Abstract

We have proposed earlier that the poor capacity of the lipocalin allergen Bos d 2 to stimulate highly allergic subjects' peripheral blood mononuclear cells could be ascribed to endogenous lipocalins and could be related to the allergenic potential of the molecule. Here, we have characterized the proliferative and cytokine responses of human T cell clones against the immunodominant epitope of Bos d 2. We observed, for clone F1-9, that a substitution of aspartic acid for asparagine in the core region of the epitope increased the stimulatory capacity of the peptide about 100-fold in comparison with the natural peptide. For clone K3-2, from a different patient, the substitution of lysine for glutamine or isoleucine for leucine in the core region resulted in about 30-fold and 10-fold increases in the stimulatory capacity of the peptides, respectively. The clones also recognized self-protein-derived peptides but not the peptides derived from other lipocalins. We suggest that the poor recognition of the immunodominant epitope of Bos d 2 can be a factor accounting for Bos d 2-allergic subjects' weak cellular responses. Suboptimal recognition of self and allergen epitopes by T cells may be of significance for the allergenicity of proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12778490     DOI: 10.1002/eji.200322952

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy.

Authors:  Anu K Immonen; Antti H Taivainen; Ale T O Närvänen; Tuure T Kinnunen; Soili A Saarelainen; Marja A Rytkönen-Nissinen; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

2.  Reply to the letter to the editor concerning the review Immunotherapy for pet allergies.

Authors:  Tuomas Virtanen
Journal:  Hum Vaccin Immunother       Date:  2018-04-11       Impact factor: 3.452

3.  Immunotherapeutic potential of the immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues.

Authors:  Soili A Saarelainen; Tuure T Kinnunen; Cécile Buhot; Ale T O Närvänen; Anu K Kauppinen; Marja A Rytkönen-Nissinen; Bernard Maillere; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-10-16       Impact factor: 7.397

Review 4.  On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy).

Authors:  Martín Candia; Bernhard Kratzer; Winfried F Pickl
Journal:  Int Arch Allergy Immunol       Date:  2016-09-20       Impact factor: 2.749

Review 5.  Inhalant Mammal-Derived Lipocalin Allergens and the Innate Immunity.

Authors:  Tuomas Virtanen
Journal:  Front Allergy       Date:  2022-01-27

6.  Human CD4+ T cell responses to the dog major allergen Can f 1 and its human homologue tear lipocalin resemble each other.

Authors:  Aino L K Liukko; Tuure T Kinnunen; Marja A Rytkönen-Nissinen; Anssi H T Kailaanmäki; Jukka T Randell; Bernard Maillère; Tuomas I Virtanen
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240

7.  In silico analysis of a major allergen from Rattus norvegicus, Rat n 1, and cross-reactivity with domestic pets.

Authors:  Marlon Munera; Neyder Contreras; Andres Sánchez; Jorge Sánchez; Yuliana Emiliani
Journal:  F1000Res       Date:  2019-10-01

8.  Commentary: Allergen and Epitope Targets of Mouse-Specific T Cell Responses in Allergy and Asthma.

Authors:  Tuomas Virtanen; Marja Rytkönen-Nissinen
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.